IBEC is on the Steering Committee of a Future Emerging Technologies (FET) Flagship proposal, the Personalised Health Care Initiative in Europe.
The large-scale initiative, if granted, will address the grand challenges of developing regenerative, precision and personalized medicine to improve the quality of life of billions of patients worldwide.
Coordinated from the University of Minho in Portugal, Personalised Health Care has a huge partner and supporter base of more than 125 academia and health institutes, 35 research institutes, 85 industry and associations, and 20 authority representatives. IBEC Director Josep Samitier and group leader Elisabeth Engel are among the 17 members of the steering committee, which includes academics and industry leaders from ten European countries, and the only ones from a partner located in Spain.
Specific scientific goals of the Personalised Health Care initiative will be to produce patient-matched tissues and organs to overcome the shortage of organs for transplant and associated immunosuppression; the regeneration or enhancement of organs and tissues in the body; and the development of targeted and specific therapies for age-related diseases. It will also increase awareness and acceptance among the population of new technologies such as gene editing and gene therapy, optogenetics and stem cells, and cope with the regulatory framework, marketing and cost of the new advanced therapies being developed.
FET Flagships are one of the most prestigious, highly-funded, strongest and game-changing instruments of EU research, with a total budget of about €1billion. So far only two FET Flagships have been approved: Graphene and the Human Brain Project. If successful in the 2018 call, Personalised Health Care will be expected to run for about 10 years under the next framework program, FP9.
For more information, check out the Personalised Health Care Initiative in Europe website here.